The Founding and Growth of On-Q-ity: Developing Advances in Personalized Medicine
Daniel Dornbusch1 and Mark J. Ahn2
1Novartis International AG; 2Atkinson Graduate School of Management, Willamette University
Summary and key issue/decision: This case focuses on On-Q-ity, a personalized medicine diagnostics company uniquely positioned to capitalize on current and future diagnostics market opportunities. The company faces critical strategic, therapeutic, and investment decisions about how to develop high-risk, high-reward products. . On-Q-ity will need to balance lowering development risks with increasing product opportunities and competitive positioning.
Companies/institutions: On-Q-ity, US Food and Drug Administration (FDA) Division of Laboratory Services
Technologies: circulating tumor cells (CTCs) and DNA repair pathways, important elements of detecting and diagnosing cancer.
Stage of development at time of issue/decision: On-Q-ity was formed as a merger of two companies and raised a significant sum from prominent venture capital investors.
Indication/therapeutic area: Oncology
Building the Case for Biotechnology is published by Logos Press